 All right, I think we'd like to go ahead and get started today. I'm Rex Chisholm, for those of you that don't know me, and Terry Minolio and I are the co-chairs of this meeting. We're very excited to have all of you here. We think this is a really timely and important topic to be discussed, the idea of research directions in genomic medicine implementation. Just curious, how many of you have attended genomic medicine? One of these genomic medicine, this is the 11th one. How many have attended one in the past? So a vast majority of you, so that's good to see. Many. For those of you that don't know the history, this began actually in 2011 in a relatively impromptu meeting that was held at O'Hare. It was simply organized by saying, we want to find out what's going on in the area of genomic medicine, and if you're doing something and want to pay your own way to come to a meeting at O'Hare and talk to people like-minded folks about this, here's a date. And we're going to start at 8.30, so please show up. And surprisingly, we had, at the O'Hare Hilton, we had a room full of people. I think there were probably almost 50 people at that meeting. And it was really sort of testing the waters about where we were with genomic medicine at that point. I think we've come a long way since that meeting in 2018. We've had, this will be the 11th, so we've had 10 complete meetings of the Genomic Medicine Program sponsored by the Genome Institute. It is overseen, and many of the people sitting, I think at this end of the table, are members of the Genomic Medicine Working Group that is, I guess, subcommittee of the NHGRI Council. So once you're a member of the council, they put you in desert servitude, and so you end up doing things like this, but it's delightful. So just to set the stage, I think with that history, our last meeting, and many of you may have seen the very nice paper that came out in clinical pharmacology, easy for me to say, about pharmacogenomics, and then prior to that was bench to bedside that was published nicely in cell, so hopefully we'll be able to do something equally interesting with this meeting, and I think the topic, again, as I said, couldn't be more timely. So given that the idea is research directions in the implementation of genomic medicine, we really have four objectives that we want everybody to keep in mind as we go through today, and they're listed in the books so that you can refer to them regularly. First of all, I want to summarize the status of genomic medicine implementation. So all of the people that are presenting at the meeting today are people that I think can tell us interesting stories about their successes, travails, lessons learned from implementing, trying to implement genomic medicine. We also want to identify obstacles to genomic medicine implementation. We know there are a few, if not many. This is a non-trivial activity, and it's one that some people would argue maybe is still ahead of its time, and so I think that's going to be an interesting theme for us to consider today. But we don't want to just identify problems. We want to try to figure out, okay, what are the solutions to those problems and how can we take advantage of this going forward? We want to define where clinical implementation of genomic medicine could or should be in five to ten years. Predicting the future is always very difficult, and I always find myself imagining things are going to take a lot longer than they do, so I think maybe thinking about where we're going to be in five or ten years is a good task for us to sort of do as a thought experiment. And then finally, as an important part of the NHGR strategic planning process, and more about that in a bit, we're going to have some discussions about, you know, how does genomic medicine participate in the plan of the Human Genome Institute going forward? And I've got to say, there's always a healthy tension between fundamental basic genomics and implementation genomics in the institute, and I think detailed discussion about that will probably be very helpful to the NHGRI staff that's in attendance. So I think maybe just a couple of housekeeping things, those of you that haven't found them yet, the restrooms are up the stairs on the right as you go outside of the room. And I think with that, we're ready to start. So Terry, what else would you like to add? No, I think that's, I think you've covered it, and again, add my welcome and my apologies for the organization of the room. We're sorry to have sort of two tiers. We put the speakers and the moderators on the inside so that they wouldn't be tripping over anybody because we don't have great confidence in their walking abilities. But please be sure that, and Eric, we're going to do introductions before, but anyway. So please, those of you wherever you are, we made sure that you all had microphones and we really do want you to participate. It's a little hard to see some of you, so wave your hand or speak up if we're missing you. We do have for the speakers some really obnoxious signs to get you to stop talking so you get a five-minute and a one-minute and a time's up. I'm not sure they can see them from up there. Well, but you can see green and yellow and red. So we had told you... We do have a timer, but at the bottom of the table. Okay, great. So there's a timer there. Now we had told you 15 to 18 minutes, so the timer starts flashing red at 15 minutes. If you really feel obligated to keep talking, we'll let you go for another couple. But we do want to have a chance for people to ask any clarifying questions of each speaker before we go on to the full discussion. So please allow it for that. We'll have a picture at the tomorrow of the whole group, so hope that you'll join us for that. And there will be people coming in a little bit later today, a couple of people ducking out for conference calls or are on them now, and we'll be back in. So with that, I think Teji, is there anything else I needed to cover? Oh, one other thing I should mention. You are on live stream TV, so be a little bit careful about what you might be saying or doing. And all of these meetings are actually webcasts except for the first one, but they're all live streamed and then they're archived on our meeting page, as are all of the slides and the summaries from the meetings. So all of those will be available if you want to look back and see what we did in previous meetings there as well. Sorry, Teji. No, I think we're all set. Just lunch is going to be served right out here in the Fairway Garden, also at 12.30. Wonderful. All right. So we did want to do introductions because we'd like everyone to know who everyone is. There are pictures in the meeting book, but still let's just go around. So I'm Terry Minolio. I lead the Division of Genomic Medicine at NHGRI. Eric Green is up there. Who is the director of NHGRI? I'm Carmen Loud. Mary Relling, St. Jude Children's Research Hospital in Memphis. Tennessee. Dan Roden, Vanderbilt University Medical Center, VUMC, also in Tennessee. David Chambers, Deputy Director for Implementation Science in the Division of Cancer Control and Population Sciences at the National Cancer Institute. Lori Orlando, I'm at Duke University. Alana Kolchak-Romit, Geisinger. Hi, Carol Hurrow. It's at Mount Sinai, New York City. Gail Jarvik from the University of Washington in Seattle. Larry Bab from Broad Institute in Massachusetts. Chris Shoot, Johns Hopkins. Anastasia Wise, NHGRI. Cecilia Tamburo, Program Analyst at NHGRI. Gabriel Batsley, Program Analyst at NHGRI. Harvard Green, Harvard Medical School. Bob Nussbaum, CMO at Envite. Tempest Labs. Lincoln-Nate, all that, Intermountain Healthcare. I think you may need to press a button there. Well, but Bob made it louder. Blue is on. Blue is on. Can you hear me? Yep. Can you hear it, Elvira? Can you hear it, Maura? I'll use this one. Lincoln-Nate, all that, Intermountain Healthcare. Lisa Basterash of Vanderbilt University Medical Center. Kristin Wiesen and Weitzel from University of Florida. Erin Rakes, Geisinger. Laura Lyman Rodriguez from the National Human Genome Research Institute. Pat DeBurke, American Institutes for Research in Chapel Hill, North Carolina. Jeff Ginsburg from Duke University. Mark Williams, Director of the Genomic Medicine Institute, Geisinger. Rex Chisholm, Northwestern University Medical School in Chicago. Go over here. Holly Dilks, Sarah Cannon in Nashville. Bob Fremeth, Mayo Clinic. Stephen Kingsmore, I'm a local. Rady Children's Institute for Genomic Medicine, which is affiliated with Rady Children's Hospital here in San Diego. David Dimmock from the same place. Liz Murthy from Hudson Alpha Institute in Huntsville, Alabama. Olivia Harris-Mendy, Moores Cancer Center, UC San Diego. Ali Torquemani, Scripps Research Institute, about a block down the street. Dr. Mass General of the Broad Institute. Klesson Turner, Welter Reed, National Military Medical Center. Bob Wilden, University of Vermont Network. Todd Scor from Indiana University. Dick Gornschelbaum, Mayo Clinic. Teji Rock-Roberts, Dick University. I think we are having some challenges with the microphone, so please do your, that was a practice. Some of us failed. So please do your best to be sure that you're speaking firmly and it's echoing so that the people on the phone or on the webcast can hear you. With that, we have... Casey, could you introduce yourself? Casey Taylor, Johns Hopkins University. Great, and then next to Chris Chute, so I'm sorry. Hi, Gail Trevitz, Harvard Medical School. Oh, Gail, great, welcome. Super. All right, I think with that we're ready, so Eric Green is going to tell us about the Genomics 2020 strategic plan.